Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP-006 Personalized Tumor mRNA Vaccine for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
NCT07334574Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of XP-006 in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Ruijin Hospital. Primary endpoints: Dose-limiting toxicity at 21 days and Maximum tolerated dose at 21 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
XP-006
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT07334574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334574.